low molecular weight heparin & ischaemic stroke
There is mixed trial evidence concerning the use of low molecular weight heparin (LMWH) in patients with acute ischaemic stroke.
Some trials suggest a reduction in mortality/dependency at six months in those treated with LMWH.
However recent evidence suggests that LMWH has no significant benefit over aspirin for acute ischaemic stroke in patients with atrial fibrillation.
Last reviewed 01/2018